Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1962-1963

  Popat, Sanjay ^a,b   Vieira De Araújo, Alexandra ^c   Min, Toon ^a   Swansbury, John ^a   Dainton, Melissa ^a   Wotherspoon, Andrew ^a   Lim, Eric ^d   Nicholson, Andrew G ^b,d   O'Brien, Mary E R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ERLOTINIB; NAVELBINE;

AGED; ALK GENE; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG RESPONSE; EGFR GENE; EXON; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME;

EID: 80054911665     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822eec5e     Document Type: Article

References (5)

1. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
2. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9:188.
3. Kuo YW, Wu SG, Ho CC, et al. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010;5:2039-2040.
4. Tiseo M, Gelsomino F, Boggiani D, et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011;71:241-243.
5. Camidge DR, Hirsch FR, Varella-Garcia M, et al. Finding ALK-positive lung cancer: what are we really looking for? J Thorac Oncol 2011;6: 411-413.